Palatin Initiates Dosing in Phase IIa Hypertension Study
Posted on: Wednesday, 21 May 2008, 12:00 CDT
Palatin Technologies has initiated dosing in a Phase IIa clinical study of PL-3994, a long-acting natriuretic peptide receptor A agonist, in subjects with controlled hypertension.
The study is placebo-controlled and double-blinded, and will include up to five cohorts receiving escalating doses. As many as 35 subjects will be included, with six active subjects and one placebo subject per dose cohort. Subjects passing screening are admitted to a research clinic, placed on a controlled diet and have baseline blood pressures and laboratory values monitored for 24 hours.
The next morning, subjects receive a single dose of PL-3994 or placebo with blood pressures and laboratory values monitored for 24 hours. Every other week, another cohort of subjects will receive a higher dose of PL-3994 until a pre-specified blood pressure decrease is observed.
Based on the results of this study and the previously completed Phase 1 trial in healthy, non-hypertensive volunteers, a Phase II trial in patients with episodes of hypertensive urgency is planned for later 2008. Palatin is also developing PL-3994 for the treatment of acute decompensated congestive heart failure and plans to initiate a separate Phase II study in these patients later 2008.
Source: Datamonitor
Related Articles
- BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza
- MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints
- Chimerix Completes Phase I Study and Initiates a Phase II Multi-dose Clinical Trial for CMX001
- Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis
- Phase 2 Study Suggests That Extended Dosing of Aranesp(R) is As Efficacious As Weekly Dosing
- Liraglutide Provides Significantly Better Glucose Control Than Insulin Glargine in Phase 3 Study
- Rheologics Announces Phase I Clinical Study on Blood Viscosity and Peripheral Vascular Disease
- ViroPharma and Wyeth Initiate Dosing in Phase 2 Study of HCV-796 in Treatment Naive Patients and Non-Responders
- Axonyx Announces Completion of the Multiple-Dose Phase I Study of Posiphen(TM)
- Memory Pharmaceuticals Completes Dosing of Phase 1 Study of MEM 3454
 |
 |
User Comments (0)
RSS Feeds